Bayer Chief Worried About Innovation, Spanish Debts
This article was originally published in The Pink Sheet Daily
Bayer's chairman, Marijn Dekkers, calls for a greater appreciation of pharmaceutical inventors and brands, as the diversified Big Pharma reported group sales up 4% in 2011, and profits up 90% on lower charges.
You may also be interested in...
Europe was a tough market for the drugs industry in 2012, with governments imposing austerity measures and price cuts on medicines that hit companies hard. The euro survived, preventing further disruption of the marketplace, but little respite is expected in the next 12 months for patients and companies alike from clampdowns on health care spending in general, and medicines reimbursement in particular.
The radiotherapeutics sector is attracting a new and diverse group of biopharma players hoping to capitalize on the potential advantages offered by newer therapeutic radioisotopes.
Italy's Philogen is to evaluate alpha-particle emitting actinium as the cytotoxic payload for its angiogenesis-targeted monoclonal antibody platform, under a collaboration with New Jersey-based Actinium Pharmaceuticals.